|1.||Lychkova, A E: 3 articles (05/2009 - 01/2007)|
|2.||Reztsova, V M: 2 articles (05/2014 - 11/2013)|
|3.||Krupin, V A: 2 articles (05/2014 - 11/2013)|
|4.||Ermakova, N N: 2 articles (05/2014 - 11/2013)|
|5.||Reztsova, A M: 2 articles (05/2014 - 11/2013)|
|6.||Khmelevskaya, E S: 2 articles (05/2014 - 11/2013)|
|7.||Pershina, O V: 2 articles (05/2014 - 11/2013)|
|8.||Dygai, A M: 2 articles (05/2014 - 11/2013)|
|9.||Stepanova, I E: 2 articles (05/2014 - 11/2013)|
|10.||Skurikhin, E G: 2 articles (05/2014 - 11/2013)|
|1.||Pituitary Neoplasms (Pituitary Adenoma)
09/01/1997 - "The aim of this study was to define whether assessment of the uptake of [18F]fluoro-ethyl-spiperone (FESP) with positron emission tomography (PET) could be helpful for the differential diagnosis of pituitary adenomas and other parasellar lesions, and for establishing the appropriate therapeutic approach. "
04/01/1987 - "Dopamine receptors on human pituitary adenoma membranes were characterized using [3H] spiperone as the radioligand. "
09/01/1997 - "Differentiation of clinically non-functioning pituitary adenomas from meningiomas and craniopharyngiomas by positron emission tomography with [18F]fluoro-ethyl-spiperone."
01/01/1984 - "Binding studies of [3H]-spiroperidol, a potent dopamine antagonist, were performed on dispersed cells obtained from 2 mixed PRL- and GH-secreting adenomas, 3 GH-secreting adenomas and 4 'nonsecreting' pituitary tumors. "
09/01/1987 - "Dopamine receptors in the 7315a transplantable rat anterior pituitary tumor were characterized using radioligand binding assays with [3H]spiroperidol ([3H]SPD) and assays of adenylate cyclase activity. "
12/01/1984 - "One of them seems to be responsible for inducing neuroleptic-like catalepsy, and the other one for the hyperactivity and blockade of spiperone-catalepsy."
07/01/1980 - "It neither affected the spiperone-induced catalepsy nor was active in the behavioural despair test in rats. "
05/01/1978 - "4 This same dose range of spiperone (0.005 to 0.05 mg/kg) attenuated locomotor activity, whether spontaneous or evoked by non-contingent electrical stimulation, and produced catalepsy. "
07/01/1988 - "Catalepsy scores of rats receiving spiperone decreased over the course of treatment, with a significant reduction in catalepsy occurring by treatment day 5. The profound catalepsy observed in rats receiving SCH23390 did not change over the 21 d of treatment. "
05/01/1994 - "7-CKA given icv did not influence the spiperone-induced catalepsy as well as the anticataleptic effect of CGP 37849. "
|3.||Body Weight (Weight, Body)
05/01/1992 - "Although the ratio of left ventricular weight to total body weight was significantly increased 14 and 28 days after aortic constriction in animals, [3H]spiperone binding in left ventricular membrane was increased as early as 3 days after aortic constriction. "
03/01/1981 - "In addition, incremental reductions in 5-HTP-induced drinking with increasing doses of spiperone (37.5 to 150 microgram/kg body weight, IP), a more potent dopaminergic antagonist, were demonstrated. "
01/01/1981 - "Acrylamide did not affect the number, size, or body weights of litters obtained but did decrease the [3H]spiroperidol binding in striatal membranes of 2-week-old pups. "
09/01/1995 - "Significant decreases in body weight and in [3H]-spiperone binding were observed at all ages studied in the corn-based diet groups with respect to controls at the first postnatal day of age, whereas at the 18th gestation day, the [3H]-spiperone binding was higher in the protein restricted and corn-lysine supplemented group than in the control group. "
08/01/1992 - "Exposure to acrylamide (2 mg/kg body weight) in protein-malnourished pregnant rats caused a marked decrease in the activity of monoamine oxidase and acetylcholinesterase and also in the binding of [3H]spiperone, [3H]QNB, and [3H]diazepam to striatal, cerebellar, and frontocortical membranes, respectively. "
08/01/1976 - "Acute administration of the dopaminergic blocking agents chlorpromazine, spiroperidol, and clozapine eliminated MA-elicited dyskinesias, whereas the alpha-adrenergic blocker phentolamine was ineffective. "
01/01/2001 - "To assess the role of dopamine receptors in the genesis of dyskinesia, we have used quantitative autoradiography to determine the effect of chronic L-dopa administration on dopamine D-1 (using [3H]SCH 23390), D-2 (using [3H]spiperone) and D-3 (using [3H]7-OH-DPAT) receptor binding levels in the striatum of dyskinetic or non-dyskinetic monkeys. "
09/01/2013 - "This hypothesis has been supported by animal experiments which have replicated the protective effects of bright light against the development of myopia under laboratory conditions, and have shown that the effect is, at least in part, mediated by dopamine, since the D2-dopamine antagonist spiperone reduces the protective effect. "
|6.||Monoamine Oxidase (MAO)
|8.||Adrenergic Antagonists (Antiadrenergic Agents)